Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galvokimig in moderate to severe atopic dermatitis
NCT07277660Phase 2Active, not recruiting
- Sponsor
- UCB
- Start
- Dec 2025
- Primary completion
- May 2027
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of galvokimig in atopic dermatitis (AD), sponsored by UCB. Started Dec 2025; status: active, not recruiting.
02
Drugs
galvokimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07277660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277660.